Danish pharmaceutical giant Novo Nordisk (NVO) might not be a household name, but its flagship products have probably been lighting up your socials for a while now. We’re specifically talking about Ozempic and Wegovy, which have become part of a daily routine for around 100 million people worldwide.
Nobody can deny these weight-loss wonder drugs have made a considerable impact on people's lives, and they’re likely alleviating a lot of pressure on healthcare systems around the world. But Novo has a growing direct-to-consumer business, and every market has a saturation point.
That’s why the company’s chief scientific officer has started teasing the company’s entry into the hair loss vertical, and it actually makes perfect sense. According to Novo’s Martin Lange, a lot of the science behind curing baldness has its roots in endocrinology. This is an area the company has decades of experience with, and so hair loss has been earmarked as a new opportunity with a lot of potential.
Before you run out and start speculating, it’s important to remember this is all talk right now. Novo hasn’t got a magic baldness pill ready for FDA approval. But if you follow Big Pharma, this talk does actually tell us a lot about its direction of travel and where one of the sector’s biggest players thinks its next billion-dollar opportunity will come from.
Novo Has a Weight-Loss Problem
At first glance, it might look a bit odd for the maker of two of the world’s biggest drugs to suddenly start thinking about hair loss. But the truth is Novo needs to start looking beyond weight loss if it wants to sustain growth.
Why? Because competition in the weight loss market is getting intense.
Next-generation obesity drugs like Eli Lilly's (LLY) Zepbound are putting a lot of pressure on Wegovy. Meanwhile, Novo has to start preparing for the expiration of its semaglutide patents. Semaglutide is the active ingredient in the company’s popular GLP-1 drugs, and the company’s patents have already lapsed in China and India.
That’s part of the reason shares have been in pretty steady decline since 2024. Things aren’t going horribly. Novo’s Q2 sales were up 7% at constant exchange rates, and the company raised its full-year sales outlook in August. But at the same time, Novo hasn’t given investors a lot of hope that it can replace the extraordinary growth generated by Ozempic and Wegovy.
Now, it looks like the company’s new strategy is to avoid putting all its eggs into the weight loss basket. At its September Capital Markets Day in London, Novo introduced five new multi-blockbuster drugs it wants to bring to market by 2030. According to CEO Mike Doustdar, these drugs should bring in about $23 billion in risk-adjusted pipeline sales by 2035.
Baldness doesn't seem quite so random anymore, does it?
The hair-loss business has been growing in recent years, and it’s got one major attraction that obesity treatment doesn’t: Patients are willing to pay for treatment out of pocket. A lot of Novo’s GLP-1 customers are public health providers on long-term fixed contracts. When you’re selling directly to consumers rather than relying on doctors or insurers, there’s no politics and a lot more flexibility.
That doesn’t mean Novo will instantly crack the science and patent a cure for baldness overnight. Hair follicles are complicated, and existing treatments like minoxidil have limitations and often fail to deliver. But the company’s breadth of experience with hormonal drugs and huge operational machine definitely gives it a leg up on the competition.
Novo Isn't Just Betting on Baldness
Although this hair loss stuff could unlock some major growth for Novo, it’s worth noting that this is just one strand of a bigger transformation happening at the company.
The company recently dropped “Nordisk” from its day-to-day marketing materials, has come out with a new slogan, and claims its strategy is designed to place consumers in charge of their own healthcare. That corporate speak isn’t difficult to translate.
Novo’s goal isn’t to rely on a handful of blockbuster drugs. It wants to worm its way into the broader consumer health economy, and the timing makes perfect sense. The company has built a huge direct-to-consumer business with Ozempic and Wegovy and learned how to market prescription medicine to buyers.
Now, Novo has multiple brands that are recognized beyond traditional pharmaceutical circles. Its only hope of sustainable growth is to exploit that recognition with extensions to the model. It’s looking into menopause drugs, addiction treatments, and now hair loss. But as ever, the proof is in the pudding.
Novo hasn't announced a hair loss program, and right now this is only an area of interest rather than a product we’re about to see on shelves. That being said, this is still good news for investors who care about Novo’s overall strategy and direction of travel.
The GLP-1 boom is slowing down, and so is Novo’s grip on the market. Now, it looks like the company has finally settled on a plan to show the world it’s not a one-trick pony. There’s a lot of work to do before that plan translates into soaring stock prices, but at least now shareholders have reason to hope.
On the date of publication, Nash Riggins did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.